The current financial score of Teva Pharmaceutical Industries Ltd is 8.35. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.37B, representing a year-over-year decrease of 2.24%, while its net profit experienced a year-over-year decrease of 46.19%.
The current valuation score of Teva Pharmaceutical Industries Ltd is 8.30. Its current P/E ratio is 36.14, which is 45.84% below the recent high of 52.70 and 583.73% above the recent low of -174.80.
The current earnings forecast score of Teva Pharmaceutical Industries Ltd is 8.67. The average price target is 49.78, with a high of 57.00 and a low of 42.12.
The current price momentum score of Teva Pharmaceutical Industries Ltd is 3.60. Currently, the stock price is trading between the resistance level at 46.33 and the support level at 40.89, making it suitable for range-bound swing trading.
The current institutional shareholding score of Teva Pharmaceutical Industries Ltd is 5.00. The latest institutional shareholding proportion is 62.27%, representing a quarter-over-quarter increase of 7.66%.
The current risk assessment score of Teva Pharmaceutical Industries Ltd is 8.00. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.